Reddit Posts
I’m 27 and need advice on investing, still new as I just started a couple months ago
Biotech Catalysts This Week ($VSTM $ABUS $ASXC $NMTR $RIGL $PGEN $CTIC $LCTX $ASLN $ZYNE)
#premarket #watchlist 09/20 $VSTM - Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 , $CRVS - no news , $APRE - upcoming presentation of data for eprenetapopt in combination with pembrolizumab for the treatment .... Any trading ideas? Welcome in comments! Also check my app.
Biotechs With Potential Catalysts This Week: $SPPI $VSTM $APRE $CAPR $CFMS
VSTM - Attractive looking squeeze on a cheap to buy stock. 3.92 a share. 29 percent short interest. A biotech company with a recent FDA grant.
VSTM could easely be ready for a major breakout ,fda on cancer data approval
Mentions
I moved a majority of my main account into Googl the day after the government decided not to do anything. Best decision of my life, so far. Also made nearly $30k playing the yo yo that is VSTM. Which I completely got out of when the medicare cuts got signed into law. Moved it all into googl as well. Pharma stocks are off limits for awhile as far as I’m concerned.
If it’s a taxable brokerage, I’d go with VTI/VXUS and a percent of SHY (if you want to preserve capital and if you’re worried about market crash, go with GOVT). If you like a little spice in your life, leave a small % so you can play around with certain stocks. For me, I put a few in ICLN and PICK to name a few. My best pick so far was VSTM where I would’ve made sooo much if I’d just put in a lot of money. But I’m not that adventurous. 😂 I would also DCA.
Look at VSTM. Great value and growth there.
VSTM still pumping despite market pullback
Just so we're clear, I'm also a VSTM shareholder and optimistic about the company. The problem is that your post isn't inspiring—it's causing confusion by blending truth with inaccurate information. Please, don't deny the facts.
Did you figure out the google.machine yet and see the 2 different institution purchases? Google search "VSTM SEC FILES"
Im holding forever or until a buyout. They already got the drug approved for ovarian cancer and realized its good for lung and pancreas after. Now they are going through the process to get it approved for those other types of cancer. They are presenting monster data this weekend and that should spike it as well. This will be a 10 billion market cap in 2-3 years. Im not going anywhere. This is the stock that splits multiple times in the future and goes up exponentially. Firms know it as well. 10 million shares purchased by firms in the last 60 days. You can view it on the sec website. $VSTM gang for life....or until I make millions lol.
VSTM hello? Someone help
Dude, just when I was convinced all pharma plays were cursed, VSTM pulls this wild move. Congrats on the gains! 💰🚀 But fr, how many of us set alerts for FDA approvals? Need that Big Brain energy! 👀
VSTM been on the up for a month. Would love some options but no one's touching it. I'm guessing we're near the top
Where's the top for VSTM? Can't tell why they've been on a burner for the last month.
I bought rocket lab at 7$ sold at 20$ 😭 and I heard all of those stocks currently hold PGEN with the fda approval that’s how I got VSTM at 4$ sold at 8$ PM like hearing people do aggressive pushes we can show eachothers portfolio that’s what I do with friends if they like something and are bullish I do my research and buy some stocks a generally shoot for 1k shares and usually buy over $5 but I have an aggressive 2k on PHRRF 0.28$ but they got fda approval so hoping to sell soon
The G12D potential is there for VSTM with their lung and pacreatic cancer assets.
Also VSTM will be in a short squeeze too. The data is too strong for the 9/19 $5 put contracts. They’ll have to cover their losses
Yessir. I also hold VSTM and this is going to be a nice year for their growth
VSTM just announced positive results from phase 2 fda trial. Most effective lung cancer and ovarian cancer drug out there. Currently in phase 3. 2 firms just disclosed purchasing 1/6 th of the float with the SEC on 14 August. They are also over 39 percent short and scheduled to speak at a major event in September. They will 10x this year.
Best of luck to you too. I predict VSTM should be at $15 by EOY if the data read outs go well
Take a look at VSTM since you got collateral. Some regard just bought 150k worth of 8 dollar calls that expire this friday.....im in!!!
VSTM! let's roll on ovarian Ca tx!
Why isn’t VSTM taking off with FDA news?!
VSTM is interesting. FDA approval for their ovarian cancer drug. Supposed to be a first of its kind, but price action doesn’t reflect it… gonna park some money in and watch for the next week or so. Not a penny
https://www.stocktitan.net/news/VSTM/fda-approves-the-avmapkitm-fakzynjatm-combination-therapy-as-the-451eatsxttui.html
Thanks for your thoughtful reply—and first off, respect for being “real hard” in. You clearly care enough to think critically, which I rate highly. Let’s unpack your points systematically, because they’re valid to raise—but I think there’s a stronger case than you might realise once we zoom in on the specifics. 1. “Retail hasn’t arrived” — Is that just narrative? This isn’t just a throwaway line—it’s based on hard signals in the data: • Daily volume averages ~100–200k shares—for a float of ~32.7M, that’s thin. • The price rarely holds >$4.50, which sits right beneath major call gamma clusters (especially for 5/17 and 6/21 expiries). • Reddit, StockTwits, and FinTwit coverage remains nearly non-existent relative to microcaps with similar setups. This is not a GME-style meme crowd yet. • No major breakout candle since late 2023. Price action still governed by low-liquidity grinding. That’s what “retail hasn’t arrived” means. It’s not about absolutes—it’s about relative awareness and inflow. This still trades like a stock no one is watching, despite the late-stage asset and real pipeline. 2. “Market makers are suppressing price” — or just natural price mechanics? Fair to question, and to be clear: we’re not alleging conspiracy. But there are signs of mechanical pinning behavior that often coincide with institutional accumulation phases. • Gamma exposure (GEX) has been persistently negative across key strikes ($4.00, $5.00, $7.50), indicating dealers are short gamma and need to sell into strength as price rises. • Call volume and OI in deep OTM strikes (5–10–15) have increased, with LEAPS disproportionately stacked. This asymmetry mechanically pressures price toward max pain until hedging dynamics flip. • Dark pool volume remains >50% most days, based on FINRA TRF and off-exchange prints. That suggests algo-mediated accumulation or suppression, not natural retail trading. These aren’t accusations—they’re structural facts of how illiquid options-driven stocks behave when institutions are building exposure and market makers are net short gamma. 3. “Gamma squeeze impact is overhyped in small biotechs” True if the float is large and options OI is low. But in this case: • Short interest is 12.23% of float, with ~10.7 days to cover . • Options OI at May/June 5, 7.5, 10 strikes is significant relative to ADV. • Gamma exposure flips around $5, which coincides with LEAP hedging thresholds and dark pool volume drops. When price starts moving with volume, dealers must delta hedge, which can mechanically escalate the move—even in small caps. See ARDS (2021), RLAY, and VSTM for examples of micro-cap biotechs with small floats that moved violently due to options-based dislocations. 4. “You glossed over the risks” Absolutely fair. Let’s confront them: a) Phase 3 failure risk Always real. But efzofitimod has: • Peer-reviewed Phase 1b/2a results: +180mL FVC (p=0.035), 85% relapse reduction • Clean safety, no deaths, and no withdrawals due to adverse events • A running Expanded Access Program (EAP) before readout—a rare vote of confidence from FDA and clinical partners • Mechanistic validation published in Science Translational Medicine: NRP2 binds inflammatory macrophages and reprograms them to pro-resolving states This isn’t a black-box biotech praying for a signal. It’s a de-risked candidate with multiple converging confidence signals. b) Funding / dilution ATYR has adequate runway through Phase 3 readout. Japan progress payments come into play too. More funding will come—but after the value-inflecting catalyst, not before. Also worth noting: insiders are buying. Director Jane Gross purchased 3,750 shares on March 17, 2025—bringing her total to 9,750. Not a large amount in dollars, but symbolically important during a pre-readout period . c) Adoption risk Pulmonary sarcoidosis is a high-unmet-need market. The standard of care is steroids, which are toxic and non-curative. There is no FDA-approved disease-modifying therapy. If efzofitimod gets approved with even modest payer support, uptake could be swift—especially since many patients are already on it via EAP or compassionate use channels. 5. So what’s the core disagreement? It comes down to how you weigh the coiled structure: • Float is small (~32.7M), with >12% short and heavy institutional ownership • Valuation is absurdly low ($300M) vs $500M–$700M rev potential in just sarcoidosis • Scientific, regulatory, and market signals are all aligning • Options chain and volume profile reflect a classic pre-breakout structure This isn’t hype—it’s an asymmetric setup where fundamentals, market structure, and psychology are beginning to converge. Happy to debate any of this, but I hope the added facts help clarify where I’m coming from. There’s a whole lot more that I could add. I respect skepticism—especially in biotech. But this setup is rare, and all the ingredients are in place. Let’s see what happens.
calls on VSTM MNMD ASTS LUNR
Thank you to the redditor who posted about VSTM
#VSTM Jesus people are stupid and miss actual good buying opportunities
#VSTM Jesus people on this sub are stupid and constantly miss actual good buying opportunities
VSTM has 13 Drugs currently in its pipeline, 1 Of which is at the end of Phase 3 (RAMP301) 6 Of which are at the end of Phase 2(IST-Frame)(RAMP201)(IST)(RAMP202)(RAMP205) Data was published last Thursday and crazy enough the data was good yet there was a 20% sell off which actually isn't that bad and gave the RSI some cool off time. Across the board every analyst believes the stock is undervalued ridiculously, I think this is due to no one really paying that much attention to it, on top of that last quarter was the first time they realized earnings revenue, they are expected to release Q4 Earnings in November and expected to beat both EPS and Revenue again. Main institutional investors are Blackrock, Vanguard, and Jefferies ( Blackrock in particular just bought 1million more shares not that long ago ) This is a bio stock that was forgotten about not to long ago but with all of the data coming out and FDA approvals and fast track programs they're are starting to come back up again On the TA side of things we just broke a long downtrend and have been placed right above the trend lines, break out imminent, any PR would literally catapult into the 10s. TL:DR This is a very very good time to accumulate shares and hold for less then a year for potentially 5-10X gains, even short term ( 2-3weeks ) I see that lowest PT (7$) being hit what are yalls thoughts?
#VSTM Seriously check it out 👀🧐
#VSTM Book value 22$ Per Share trading at 3.7$ Just released Phase 2 All Analyst in past month say above 14$ 👀🧐
**Top % Gap Up:** $NUZE +314% $DRMA +130% $SGMO +88% $BBLG +72% $PIRS +66% **Top % Gap Down:** $AZTR -75% $NUWE -37% $CONN -37% $ATPC -27% $VSTM -25%
VSTM hurt a lot of longs, but it's a buy for me currently.My average 2.95 and average 12 month analyst price target is 20 dollars . Loading regularly
Verastem, $VSTM has just been added to the Russell 3000 and Microcap and has barely moved up from an oversold position. However, odds are it will be moving up strongly with the added prestige
Sometimes that shit happens for no reason. Case in point $VSTM
Verastem $VSTM dropped below 4.00 recently making it officially a penny stock. Looks like investors overreacted recently sending it into deep oversold territory. Company has expressed upbeat attitude toward coming data. If news is positive could double in price
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Verastem, Inc. (“Verastem” or the “Company”) (NASDAQ: VSTM). Such investors are advised to contact Danielle Peyton at [~newaction@pomlaw.com~](https://www.globenewswire.com/Tracker?data=TjjvYWLBNtcw45lA77AXmCR7gdboQQVgVYvxCkTcvPOOtBN5qog5v_R72Jg7XWFcCGY1hetwSsrtYqSFM65W6fyza6v9nlrcL4W8bluTV2M=) or 646-581-9980, ext. 7980. The investigation concerns whether Verastem and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
$VSTM. Almost down 70% on Friday and potential bounce from oversold territory
$VSTM. Almost down 70% on Friday and potential bounce from oversold territory
Yea it dropped from 11-12 to 4. I think buying some would be a great idea. Candel Therapeutics fell too. Both VSTM and CADL had pancreatic cancer as a research pipeline. Side effects from the treatment affected the stock of VSTM.
Added 50k worth of VSTM on Friday, looking for a bounce to $6 at least on Tuesday
$VSTM. Almost down 70% on Friday and potential bounce from oversold territory
$VSTM. Almost down 70% on Friday and potential bounce from oversold territory
$VSTM. Almost down 70% on Friday and potential bounce from oversold territory
VSTM took a dive bomb at market open
Why is VSTM down 60% pre-market with 10x normal volume exactly 1 year after it was way up with high volumes?
VSTM was up 55% after releasing data afterhours yesterday and now is down 60% premarket. Wow.
Some big move afterhours in the biotech sector: https://www.globenewswire.com/news-release/2024/05/23/2887676/0/en/Candel-Therapeutics-Reports-Prolonged-Overall-Survival-in-Phase-2-Clinical-Trial-of-CAN-2409-for-Advanced-Non-Small-Cell-Lung-Cancer-NSCLC-in-Patients-Non-Responsive-to-Immune-Chec.html $CADL +33% https://www.businesswire.com/news/home/20240523300933/en/Verastem-Oncology-Announces-Positive-Initial-Interim-Safety-and-Efficacy-Results-from-RAMP-205-Trial-Evaluating-Avutometinib-Plus-Defactinib-in-Combination-with-Gemcitabine-and-Nab-paclitaxel-in-First-Line-Metastatic-Pancreatic-Cancer%E2%80%8B $VSTM +55%
I like VSTM. If you see a drop to 10 and lower pick some up. It usually stays around 11-12. They have several trials in the pipeline which can be viewed on the [website](https://www.verastem.com)
$VSTM July 21 $10 puts ☠️
Woah, what happened to VSTM
VSTM still running from Friday. Careful play
Put a lot into VSTM. Has a lot potential coming up
VSTM, I like hammers off the lows
I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: VSTM. Message /u/zjz if they're above 1.5 billion-ish market cap and not related to crypto/pennies/OTC.
VSTM is on the move! Let's go baby!
Also, if anyone recommends a stock to you be very cautious. Due your due diligence and don't blindly listen to what someone says. A lot of pump and dump happens on various forums where people hype up a certain stock and talking about how you can make millions, and then in a few months the stock loses like 70% of its value. It's happened to me when I bought into the hype on VSTM. A lot of articles on seekingalpha recommended this and then I went from $5 to $.7
$VSTM NEXT WEEK 
I just added: SEEL MP BGRY ALNA VSTM CRDF
VSTM just needs a little volume and it will go parabolic
VSTM is moving great today.
EDSA, ZIVO , VSTM - getting that big money bag today. With my cup of joe going to the bank 🚀🚀🚀🚀❤️
XXII 300% SNAP 250% SYF 165% SJR 79% VSTM 54% Quite proud of SYF and XXII because SYF pays a dividend and I'm up the most nominally on XXII.
Holding ATOS ILUS MLFB ABML TAWNF VSTM
still holding VSTM. Plenty of cash! Possible next VCEL! Can only hope!
VSTM - A biotech company shares are 3.92. Short interest is 29 percent. Recent FDA grants that is very promising. At that price should be pretty easy to squeeze.
My only regret with VSTM is that I didn't buy more shares.
I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: VSTM. Message /u/zjz if they're above 1.25 billion-ish market cap and not related to crypto/pennies/OTC/SPACs.
Anyone watch the VSTM presentation at the Jefferies conference? I think it’s the real deal
I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: VSTM. Message /u/zjz if they're above 1.25 billion-ish market cap and not related to crypto/pennies/OTC/SPACs.
Really need $VSTM calls to go up in value but atleast my AMC shares and calls are doing gods work
Anyone think VSTM is still on the up and up with their new therapy distinction through the FDA?
Would buying VSTM puts be smart?
VSTM is looking great right now and for long term.
Anyone trading VSTM rn?
i will continue to hold my AMC, GME, VSTM, NVIDA, and AMD, maybe hold my internet funny money and possibly buy more
Should I go all in with $VSTM ?
NOU/NMGRD Carbon-Free Graphite mine in Canada for EV batteries HEO/HEOFF H2O Innovation is a leader in customized water and wastewater treatment solutions using membrane technologies VSTM: Biopharma for treating some form of cancer QUIS: Partner with Microsoft cloud, active in India GHVI: matterport, 3D scan for real estate and virtual tour VACQ: rocket lab: aerospace manufacturer
I 100% agree. All I was originally trying to say was that an increase in auth shares isnt immediate dilution like the OP thought. At the mkt dilution is coming for sure. When and how much is a future disco. Shareholders better hope they dont do a convertible note deal though. While those deals defer the actual dilution, note holders almost always open short arbitage positions to hedge the notes. This can deflate share price and also raises debt service. I was in a spec bio trade in 2018-19 with VSTM. The second they announced the convertible note deal I sold. Price didnt stop falling for months after I sold. It wasnt all due to the note deal but some of it def was. I hate those deals